Aug. 10, 2005 — The U.S. Food and Drug Administration (FDA) approved in May revisions to safety labeling to advise that prophylactic use of fondaparinux sodium injection is associated with an ...
Fondaparinux is associated with lower risks of severe bleeding and death compared with low-molecular-weight heparin (LMWH) in patients with NSTEMI treated in routine clinical practice, supporting ...
Following a review of the overall event rates (blind to treatment allocation) after the first 4000 patients had been randomized, the steering committee implemented a protocol modification to include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results